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costs ($14,380 vs. $9,800 respectively, p≤0.05). CONCLUSIONS: Diabetes patients 
with consistently high medication adherence to oral medications or having a 
history of an HbA1c test over a five-year period had lower medical costs and 
lower inpatient and emergency room costs than their counterparts.  
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CLINICAL CHARACTERISTICS, QUALITY MEASURE ATTAINMENT, AND 
DIABETES-RELATED HEALTH CARE COSTS IN ELDERLY VERSUS OVERALL 
PEOPLE LIVING WITH TYPE-2 DIABETES MELLITUS (T2DM) RECEIVING 
METFORMIN (MET) AND SULFONYLUREA (SU)  
Lafeuille MH1, Gravel J1, Bailey RA2, Martin S2, Garber L3, Duh MS4, Lefebvre P1 
1Groupe d’analyse, Ltée, Montréal, QC, Canada, 2Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 
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OBJECTIVES: This study examined the demographics, comorbidities, clinical 
characteristics, and treatments of people with T2DM and an elderly subgroup. 
Additionally, attainment of quality goals and its correlation with diabetes-related 
costs were assessed. METHODS: Health insurance claims and electronic medical 
records from 14,532 adults with T2DM (2007-2011) were used to identify a sample 
receiving MET+SU. The index date was defined as the first dispensing of MET+SU 
after 6 months of eligibility. Clinical characteristics were assessed during 
baseline and quality measure attainment, defined as no values above specific 
thresholds (HbA1c <8%, body mass index [BMI] <30 kg/m2, blood pressure [BP] 
<140/90 mmHg, low-density lipoprotein cholesterol [LDL-C] <100 mg/dL), was 
evaluated during a 12-month landmark period after the index date. Association 
between quality measure attainment and diabetes-related costs, calculated after 
the landmark period, was evaluated using non-parametric bootstrap methods 
adjusting for imbalance in baseline characteristics between cohorts. RESULTS: 
2,044 patients (mean age: 67 years; female: 46%), including 1,283 (62.8%) patients 
≥65 years, were identified. Baseline comorbidities included cardiovascular 
disease (all patients: 25.5%; ≥65 years: 33.4%), congestive heart failure (5.9%; 
8.1%), hypertension (66.5%; 74.2%), hyperlipidemia (73.9%; 78.1%), and 
neuropathy (16.0%; 20.2%). Statins and loop and non-loop diuretics were taken by 
60.5%, 10.5%, and 21.1% of all patients, and 66.9%, 13.8%, and 24.5% of patients 
≥65 years, respectively. The proportions meeting various quality goals were: 
82.9% (≥65 years: 88.2%) for HbA1c, 34.4% (42.1%) for BMI, 31.6% (27.7%) for BP, 
and 68.2% (73.3%) for LDL-C. Quality measure attainment was associated with 
significantly lower diabetes-related costs per-patient per-year (adjusted mean 
cost differences: -$1,445 for HbA1c; -$1,218 for BMI; -$2,029 for HbA1c and BMI;  
-$2,073 for HbA1c, BMI, and BP; all P<0.05) compared to non-attainment. 
CONCLUSIONS: This study highlights the high incidence of comorbidities and 




BURDEN OF HEALTH RESOURCE UTILIZATION (HRU) AMONG INSULIN PEN 
USERS WITH TYPE 2 DIABETES MELLITUS  
Chandran A1, Bonafede MM2, Saltiel-Berzin R1, Hirsch LJ1, Lahue BJ1 
1BD, Franklin Lakes, NJ, USA, 2Truven Health Analytics, Cambridge, MA, USA  
OBJECTIVES: To characterize type 2 diabetes mellitus (T2DM) patients’ newly 
initiating insulin therapy with an insulin pen and quantify their health resource 
utilization (HRU). METHODS: Adult patients with at least one new claim for an 
insulin pen between January 2006 and September 2010 were selected from the 
Truven Health MarketScan Research Databases. Patients required continuous 
enrollment for 12 months after the index insulin pen claim, with a diagnosis of 
T2DM and one prescription for an oral antidiabetic drug. Frequency and cost of 
health care encounters were highlighted. HRU includes inpatient admissions, 
emergency department and outpatient office visits, outpatient laboratory and 
radiology services, other outpatient services and outpatient prescriptions. HRU was 
calculated separately for all-cause and diabetes-related expenditures. RESULTS: 
Nine thousand two hundred and eighty five patients met the study criteria with 
average age of 58.5 (SD=12.4); 52.9% were male. The Deyo-Charlson comorbidity 
score for this sample was 2.3 (SD=1.8). Most frequently observed baseline 
microvascular and macrovascular complications included diabetic neuropathy 
(14.7%), renal disease (16.2%), and ischemic heart disease (22.9%). Other common 
comorbidities included hypertension (47.3%) and dyslipidemia (31.5%). Patients 
frequently continued to fill oral anti-diabetic prescriptions after initiating an insulin 
pen, most commonly biguanides (46.3%) or sulfonylureas (31.8%). Concomitant 
medication use was high: most patients (83.9%) used a hypertensive, dyslipidemia 
(72.7%), anti-depressant (28.7%), or anti-emetic/nausea (9.6%) medication in the year 
after insulin pen initiation. In the year after insulin pen initiation, all-cause 
expenditures averaged $26,193 (SD=$47,670)), of which 15.8% were diabetes-related. 
Inpatient admissions accounted for 27.3% of total costs. Medication costs were 
substantial, accounting for 27.6% of total costs; 39.8% of medication costs were 
diabetes-related. CONCLUSIONS: Health expenditures associated specifically with 
T2DM patients initiating an insulin pen are substantial. Further research is required 
to explore the relationship of T2DM medication management on overall health 
resource utilization.  
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OBJECTIVES: To assess level of polypharmacy in patients with type 2 diabetes 
mellitus (T2DM) and its association with adherence to oral anti-diabetic drugs 
(OAD) and health care costs. METHODS: The Thomson MarketScan Commercial 
and Laboratory Databases 2005-2012 were used to select T2DM patients aged 18-
64 with continuous enrollment ≥2 years (the first year as baseline) who used 
OADs. Prescriptions at baseline year with at least 90 days of cumulative days-of-
supply were counted to determine level of polypharmacy according to active 
ingredient. Patients were categorized into four cohorts: no polypharmacy (≤2 
drugs), minor (3-5 drugs), moderate (6-8 drugs), and major (≥9 drugs). Adherence 
to OADs was evaluated during 12-months follow-up using mean proportion of 
days covered (PDC). Adjusted association between polypharmacy and adherence 
(PDC ≥0.8) to OAD and total health care costs were examined using logistic 
regressions and generalized linear regression models, respectively. RESULTS: Of 
the total sample population (N=13,365), 22.4% had non-polypharmacy, 39.3% had 
minor, 25.3% had moderate, and 13.0% had major polypharmacy. The 
polypharmacy cohorts had significantly higher all-cause health care costs (non-
polypharmacy: $7,482; minor: $9,144; moderate: $14,465; major: $25,072; all 
p<0.05) and adherence to OADs (non-polypharmacy: 42.0%; minor: 63.1%; 
moderate: 73.9%; major: 78.3%; all p<0.05) during the post-index period 
compared to non-polypharmacy. Annual incremental costs associated with 
polypharmacy were $1,602 (minor), $5,808 (moderate), and $13,447 (major) when 
compared with non-polypharmacy cohort. A higher level of polypharmacy was 
associated with a higher likelihood of adherence than the non-polypharmacy 
cohort (minor: OR=2.18, 95% CI=1.99-2.40; moderate: OR=3.58, 95% CI=3.20-3.99; 
major: OR=4.70, 95% CI=4.07-5.43). CONCLUSIONS: Polypharmacy was common 
and associated with high economic burden among patients with T2DM. The 
positive association between polypharmacy and adherence to OAD warrants 
further investigation of the behavioral mechanism.  
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OBJECTIVES: The primary objective was to assess the prevalence of DPN using 
Vibration Perception Threshold (VPT) using biothesiometer considered as the 
gold standard for the diagnosis of DPN. The secondary objectives of the study 
were to compare the prevalence between Known Diabetics (KD) and Newly 
Detected Diabetics (NDD), assess the neuropathy prevalence pattern and identify 
any modifiable risk factors associated with occurrence of DPN among diabetics. 
METHODS: The study was cross-sectional, observational study. Subjects were 
recruited from Endocrinology clinic of a public tertiary care hospital. Subjects 
with duration of diabetes (≤6 months) were considered to be NDD. VPT 
measurements were done to assess neuropathy (cut off ≥20V). Severity of 
neuropathy was graded into three groups based on VPT score as mild (20- 24.99 
V), moderate (25-39 V), and severe (>39 V). 791 subjects were included on a 
random sampling basis which includes 638 KD and 153 NDD. Multivariate 
analysis was performed for assessing independent risk factors associated. 
RESULTS: The median duration of diabetes was found to be 6 (2 - 12) years. 300 
subjects were found to have DPN accounting for 37.9% (95%CI: 34.5-41.4) 
prevalence. Higher prevalence was observed in KD compared to ND (43.7% Vs 
13.7%, p<0.001). The prevalence of mild neuropathy was 10.4%, moderate 
neuropathy was 18.9%, and severe neuropathy was 8.6%. Regression analysis has 
shown age (p=0.007), female gender (p=0.001), duration of diabetes (p=0.001), 
dyslipidemia (p=0.008) and presence of other microvascular complication 
(p<0.001) to be associated with DPN occurrence among diabetics. CONCLUSIONS: 
This cross-sectional study shows the prevalence of DPN to be 37.9%. Severe 
neuropathy prevalence was found to be 8.6% who were at the risk of foot 
ulceration or lower limb amputation. DPN was associated significantly with 
increasing age, early onset of diabetes, female gender and dyslipidemia.  
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OF SULFONYLUREA USE BY PHYSICIANS  
Bognar K1, Bell K2, Lakdawalla DN3, Shrestha A1, Snider JT1, Thomas N2, Goldman DP3 
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OBJECTIVES: To study the association between rates of sulfonylurea (SU) use at a 
physician’s practice and average health care costs and complication rates among 
the physician’s patients with type 2 diabetes mellitus (T2DM). METHODS: We 
performed a retrospective group-level analysis on a sample of 7,905 patients 
(214,230 patient-months) insured by Humana, aged 18-64 with an incident T2DM 
diagnosis between 2007 and 2011. We regressed physician-level monthly 
complication rates (cardiovascular, lower extremity, ophthalmic, renal, 
neuropathy, and hypoglycemia) and average health care costs on 3-month-
lagged rates of SU use controlling for use of 10 other T2DM therapy classes in 
each physician’s practice, and patient and practice characteristics. Costs  
were estimated using a generalized linear model with log link to account for 
common zero costs. RESULTS: SU use was associated with increased rates of 
lower extremity, ophthalmic, and renal complications relative to no drug  
use (p<0.05). For each complication class, we identified the best performing 
therapy and estimated the effect of a hypothetical switch in prescribing patterns 
from 100% use of this class to 100% use of SU, as percentages of the respective 
average complication rates. Our estimates were: 93% increase in cardiovascular 
when switching from meglitinides, 133% increase in lower extremity when 
switching from alpha glucosidase inhibitors (AGI), 433% increase in ophthalmic 
when switching from amylinomimetics, 47% increase in renal when switching 
from biguanides, 147% increase in neuropathy when switching from AGIs and 
252% increase in hypoglycemic complications when switching from 
amylinomimetics. Despite SU’s association with higher complication rates, the 
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association between average costs and rate of SU use was not significant. Other 
therapy classes were associated with increased costs with the exception of 
premixed insulin, meglitinides and amylinomimetics (no significant association) 
and biguanides and alpha glucosidase inhibitors (negative association). 




A LONGITUDINAL EVALUATION OF DIABETES MANAGEMENT IN 
COMMERCIALLY INSURED PATIENTS IN THE UNITED STATES  
Grabner M1, Abbott S2, Nguyen M2, Chen Y1, Quimbo R1 
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OBJECTIVES: Many patients on antidiabetics do not reach the ADA-
recommended A1c level (<7%). This cross-sectional epidemiologic study 
evaluated A1c levels and diabetes-related complications among commercially 
insured US patients receiving antidiabetics. METHODS: Patients aged ≥18 years, 
diagnosed with T2DM, with ≥1 oral antidiabetic or insulin fill and continuous 
pharmacy and medical health plan enrollment for 2008, 2009, 2010, or 2011 were 
selected from the HealthCore Integrated Research DatabaseSM, an integrated 
claims dataset representing a large national health insurer. Characteristics and 
outcomes were assessed descriptively. RESULTS: We identified 265,411 patients 
for 2008, 266,104 for 2009, 264,220 for 2010 and 229,079 for 2011. Electronic A1c 
lab results were available for 22.2% of patients. In 2008 48.2% of patients had an 
A1c <7%; the percentage of patients achieving this target decreased through 2011 
with only 44.5% achieving an A1c <7%. The percentage of patients with an A1c 
≥9% increased from 15.3% in 2008 to 17.7% in 2011. Mean A1c was 7.47, 7.55,  
7.50, and 7.62 for the years 2008, 2009, 2010, and 2011, respectively. An analysis 
of the 2011 population revealed that patients with an A1c <7% were less likely to 
have neuropathy (7.1% vs.10.5%), retinopathy (8.0% vs. 12.3%), or 
amputations/ulcerations (1.6% vs. 2.7%), compared to patients with an A1c ≥7% 
(P<0.001 for each). The 2011 average A1c for patients with versus without 
neuropathy was 7.97 versus 7.59; for retinopathy, 7.89 versus 7.59; and for 
amputation/ulceration, 8.13 versus 7.61. CONCLUSIONS: These results suggest 
that diabetes management in the US over the past four years has worsened in 
this sample of commercially insured patients, with potentially adverse cost 
consequences. Diabetes-related complications were more common in patients 
with worse diabetes control. As more than half of patients had A1c levels above 
the ADA recommendation, the study highlights the unmet need for improved 
glycemic control.  
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PERSPECTIVES ON COMPLEMENTARY DATA SOURCES IN DIABETES HEALTH 
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NETWORK AND A LARGE COMMERCIAL HEALTH PLAN  
Dalal MR1, Frimpter J2, Pan C3, Stewart J4, Johnstone B2, Gemmen E5, Reed J6,  
Vlajnic A2 
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OBJECTIVES: Diabetes FORWARD (DF) is a practice-based research network 
(PBRN) focused on Type-2 Diabetes (T2DM) health technology assessment (HTA) 
and health services research (HSR) in North America, based in primary care 
practices with electronic medical records (EMR) and enriched with 
supplementary patient- and provider-reported information. Recruitment is 
currently 9% of goal, with interest in early evaluations of how the DF source 
population might relate to other T2DM populations. METHODS: Eligible patients 
are adults with T2DM receiving pharmacotherapy, and other criteria previously 
reported. We examined the T2DM cohort of the DF-EMR, the DF population 
enrolled between March and September 2012 (DF), and members with 
continuous enrollment through 2011 in a large commercial health plan (LHP). We 
reviewed preliminary descriptive information to inform future analyses of 
patient subgroups and outcomes among populations in these data sources. 
RESULTS: DF-EMR source population (n=187,991) and DF patients (n=935) varied 
from LHP (n=719,041) in ways to be expected from sources created for different 
purposes. DF-EMR and DF had slightly greater proportions of males versus LHP, 
respectively (48.1 and 43.6 vs. 54.2%), and a US geographic distribution skewed 
toward the South (62.6 and 68.4 vs 42.0%). Insurance types reflected the nature of 
the data sources: Commercial, 51.1 and 47.4 versus 87.2%; Medicare, 41.9 and 39.8 
versus 6.1%; and Medicaid, 1.5 and 7.7 versus 0.3%. The DF population had 
slightly greater prevalence of insulin (18.6 vs. 17.3%) and oral antidiabetic drug 
(OAD) use versus LHP, reflecting the DF pharmacotherapy criterion: No OAD, 7.4 
versus 45.7%; 1 OAD, 43.1 versus 27.6%; 2 OAD, 37.4 versus 18.2%; 3 or more OAD, 
12.1 versus 8.2%. CONCLUSIONS: HTA and HSR require complementary data 
sources to translate findings into improved outcomes across patients and 
settings. This descriptive assessment begins to investigate the potential 
applicability of findings across populations from such important complementary 
data sources.  
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A FOCUS ON REAL LIFE DATA CONCERNING ANTIDIABETIC DRUGS: THE 
EXPERIENCE OF AIFA MONITORING REGISTRY  
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OBJECTIVES: Type-2 diabetes is the most common metabolic disease in Italy and 
in developed countries. It is the sixth leading chronic disease by diffusion with a 
crude prevalence of 4.9%. It is estimated that about 3,000,000 Italians suffer from 
this pathology. In the last decade, the new class of incretin-based therapies 
entered the arena, but their place in therapy remains difficult to determine 
because of limited long-term clinical data on both effectiveness and safety,  
and the high cost of therapy. Both injectable glucagon-like peptide1(GLP-1) 
receptor agonists (incretin-mimetics) and orally-administered inhibitors of 
dypeptidylpeptidase-4(DPP-4) produce a significant improvement in glycemic 
control especially when combined with metformin, similar to other second-line 
therapies, but additional advantages with respect to weight gain and overall 
hypoglycemia. In 2008 AIFA established a Monitoring Registry through which 
collecting and monitoring the safety and the efficacy profiles of new antidiabetic 
drugs. METHODS: Data collected from the Monitoring Registry from 2008 to 2011 
were analyzed. An estimation of population enrolled, NHS-expenditures and 
median cost for patients were calculated for the antidiabetic drugs which 
entered in the Registry. RESULTS: AIFA Antidiabetic Monitoring Registry enrolled 
135,954 patients for the period of observation. 79,211 patients (58%) were treated 
with DPP-4 (saxagliptin, vildagliptin and sitagliptin associated or not with 
metformin) and 56,743 patients (42%) with GLP-1 analogous (liraglutide and 
exenatide) with an economic NHS burden on Registry respectively equal to 
€34,675,414 (55%) and €28,649,091 (45%). The daily mean cost per patient related 
to the drugs included in the Registry was around €3. CONCLUSIONS: The safety 
and efficacy profiles of drugs monitored in the Italian real-world clinical practice 
are similar to those recorded during phase 2-3 registration clinical trials. Data 
collected through Registry allows performing a cost-effectiveness analysis and a 
cost-impact for NHS comparing both the monitored drugs among them and the 
other therapeutic treatments  
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PATIENT CHARACTERISTICS, ANTIDIABETIC MEDICATION USE, AND 
GLYCEMIC CONTROL IN DIABETIC NURSING HOME RESIDENTS WITH 
MODERATE TO SEVERE CHRONIC KIDNEY DISEASE  
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OBJECTIVES: To describe the demographic and clinical characteristics, 
antidiabetic medication use and glycemic control among diabetic nursing home 
(NH) residents with moderate to severe chronic kidney disease (CKD). METHODS: 
Long term care administrative data with linked clinical and functional 
assessments, demographic information, laboratory results and pharmacy claims 
were analyzed. Residents with diabetes who remained in NHs for at least 90 
consecutive days in 2008-2011 and had at least one estimated glomerular 
filtration rate (eGFR) test and one glycated hemoglobin (HbA1c) test within 1 year 
of the continuous stay were selected. Residents with moderate to severe CKD 
were identified if they had an eGFR less than 60 mL/min/1.73m2. Resident 
demographic characteristics, comorbidities, and functional status were 
summarized. Use of antidiabetic medications was assessed for the first 90-day 
period of the continuous NH stay. Proportion with glycemic control was also 
assessed. RESULTS: Of the 1005 long-stay diabetic NH residents, 338 (33.6%) had 
moderate to severe CKD. CKD residents were on average 74.4 ± 11.1 years old and 
majority of them were females (59.8%). Common comorbidities included 
hypertension (93.2%), depression (77.8%) and anemia (56.2%). 72.8% of the 
residents were receiving ≥9 medications. Less than half (42.0%) of the residents 
received oral antidiabetic drugs (OAD) or glucagon-like peptide-1 agonist, and a 
higher proportion received insulin (61.8%). The most commonly used OAD was 
sulfonylurea (22.2%), followed by metformin (13.3%). The average HbA1c was 
7.0% ± 1.5; 59.8% had HbA1c<7%, 19.2% had HbA1c >7% and ≤8%, 11.8% had 
HbA1c >8% and ≤9%, and 9.2% had HbA1c>9%. CONCLUSIONS: The prevalence of 
moderate or severe CKD is high in long-stay diabetic nursing home residents. 
Less than two thirds of the residents with CKD had glycemic control. Medication 
therapy management to achieve better glycemic control should be considered for 
NH residents particularly among those with CKD.  
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ASSOCIATION OF SEVERE HYPOGLYCEMIC EVENTS AND HOSPITAL 
READMISSION WITH TREATMENT NON-CONCORDANCE TO GUIDELINES AND 
PRESCRIBING INFORMATION IN HOSPITALIZED PATIENTS WITH TYPE-2 
DIABETES AND STAGE 3-5 CHRONIC KIDNEY DISEASE  
Chen SY1, Alas V1, Greene M2 
1United BioSource Corporation, Lexington, MA, USA, 2Georgia State University, Atlanta, GA, USA  
OBJECTIVES: To assess the association between non-concordant use of oral anti-
diabetic drug treatment (OAD) according to National Kidney Foundation (NKF) 
guidelines and prescribing information (PI) and severe hypoglycemic events and 
hospital re-admission in hospitalized type 2 diabetes mellitus (T2DM) patients 
with stage 3-5 chronic kidney disease (CKD). METHODS: This study analyzed 
electronic health records from integrated health systems across the U.S. Adult 
T2DM patients with stage 3-5 CKD, who were hospitalized between 2008 and 
2011, were identified from medical diagnoses, dialysis procedures, or laboratory 
findings. OADs prescribed on the discharge date were evaluated and considered 
not concordant if any were not prescribed according to NKF guidelines or PI. 
Separate Cox-proportional hazards models were used to evaluate the 
associations of NKF and PI non-concordance with re-admission and severe 
hypoglycemic events controlling for patient demographic and clinical 
characteristics, respectively. RESULTS: A total of 1712 patients (mean age: 68.4; 
50.5% female; 69.6% stage-3 CKD) met the criteria for NKF guidelines evaluation 
and 1552 patients (mean age: 68.2; 50.5% female; 70.6% stage-3 CKD) for PI 
evaluation. The non-concordance rate was 36.4% for NKF and 71.8% for PI. After 
adjusting for patient characteristics, patients who were not concordant to PI 
were more likely to have severe hypoglycemic events (HR: 1.62, 95 % CI: 1.11-2.37) 
and re-admission (HR: 1.36, 95 % CI: 1.16-1.61) after being discharged. On the 
other hand, we did not find any statistically significant associations between 
non-NKF-concordance with severe hypoglycemic events (HR: 1.29, 95% CI: 0.98-
